Testosterone undecanoate - Lipocine

Drug Profile

Testosterone undecanoate - Lipocine

Alternative Names: LPCN-1111

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Lipocine
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypogonadism

Most Recent Events

  • 26 Sep 2016 Lipocine completes a phase IIb trial for Hypogonadism in USA
  • 26 Sep 2016 Adverse events data from a phase IIb trial in Hypogonadism released by Lipocine
  • 10 Mar 2016 Lipocine files for patent protection for LPCN 1111 in USA, Argentina, Australia, Brazil, China, Europe, India, Israel, Japan, Mexico, New Zealand, Paraguay, South Africa, South Korea, Taiwan, Uruguay and Venezuela (Lipocine, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top